NCT04901104尚未招募不适用
Long-term Prognosis After Thymosin Alpha 1 Treatment in Patients With Sepsis: A Multicenter Cohort Study
Sun Yat-sen University0 个研究点目标入组 900 人开始时间: 2021年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 900
- 主要终点
- three years mortality
研究概览
简要总结
Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy.
Based on the preliminary clinical study (NCT02867267), this study will conduct long-term follow-up for sepsis patients to provide data support for the long-term prognosis of immunotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sepsis patients in the TESTS study Patients who discharged from hospital after recovery
排除标准
- 未提供
研究组 & 干预措施
thymosin α1 group
The patient was treated with thymosin α1 in sepsis
干预措施: Thymosin Alpha1 (Drug)
结局指标
主要结局
three years mortality
时间窗: 3 years
Mortality rate of patients treated with thymosin α1 or placebo within 3 years
次要结局
- Recurrence rate of sepsis(5 years)
- Five years mortality(5 years)
- short form 36 questionnaire(1 year)
- one year mortality(1 year)
研究者
Wu Jianfeng
chief physician
Sun Yat-sen University
相似试验
已完成
不适用
Efficacy of Thymosin alpha1 for Severe SepsisSevere SepsisNCT00711620Sun Yat-sen University366
已完成
3 期
The Efficacy and Safety of Ta1 for SepsisSepsisNCT02867267Sun Yat-sen University1,106
已完成
2 期
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant MelanomaMalignant MelanomaNCT00911443sigma-tau i.f.r. S.p.A.488
尚未招募
1 期
Efficacy and safety of Thymosin alpha 1 combined with anti-PD-1 and Apatinib in advanced gastric cancer patients failed to second line treatmentAdvanced Gastric CancerITMCTR1900002540Shanghai Dongfang Hospital
招募中
4 期
Thymosin Alpha-1 for irAE Secondary to ICIsIrAENCT06178146Jun Wang40